Ratings Surgery Partners, Inc.

Equities

SGRY

US86881A1007

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
25.83 USD -2.34% Intraday chart for Surgery Partners, Inc. -2.86% -19.26%

Summary

  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company sustains low margins.
  • One of the major weak points of the company is its financial situation.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.75 times its estimated earnings per share for the ongoing year.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-19.26% 3.26B
C-
-18.52% 16.6B
B+
+5.41% 12.87B
B
+3.98% 11.78B
B+
+4.46% 10.28B
B+
+28.07% 8.6B
B
-4.98% 7.64B
A-
+6.76% 6.76B
B-
+7.33% 6.4B
D
+48.17% 4.58B -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SGRY Stock
  4. Ratings Surgery Partners, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW